TFDP3 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- TFDP3 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100040
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- TFDP3 antibody Polyclonal Antibodies Primary antibodies
Related genes to: TFDP3 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- TFDP3 NIH gene
- Name:
- transcription factor Dp family member 3
- Previous symbol:
- -
- Synonyms:
- HCA661, E2F-like, CT30
- Chromosome:
- Xq26.2
- Locus Type:
- gene with protein product
- Date approved:
- 2004-07-15
- Date modifiied:
- 2015-11-18
Related products to: TFDP3 antibody Polyclonal Antibodies Primary antibodies
Related articles to: TFDP3 antibody Polyclonal Antibodies Primary antibodies
- Primate-specific genes (PSGs), important contributors to the origin of adaptive evolutionary novelties, are abundantly expressed in the testis. However, the specific roles of PSGs in the male reproductive system of humans and other primates are largely unknown. Here, we employed whole-exome sequencing and identified deleterious variants of TFDP3, an X-linked PSG, in eight infertile men with oligoasthenoteratozoospermia. All of the male subjects harboring TFDP3 variants presented dramatic reductions in sperm concentration, motility, and abnormal sperm morphology. Furthermore, Tfdp3-knockdown (KD) in the testes of cynomolgus monkeys confirmed the important role of TFDP3 in normal spermatogenesis in primates. Consistently, dramatic decreases in sperm concentration, motility, and abnormal sperm morphology were also observed in Tfdp3-KD male cynomolgus monkeys. More importantly, further functional studies revealed that TFDP3 deficiency activated E2F1 induced apoptosis and thus led to decreased sperm count and motility. In addition, five of the eight couples underwent intra-cytoplasmic sperm injection treatment and achieved a successful pregnancy, indicating a potentially good outcome of assisted reproduction for those with TFDP3 deficiency-mediated oligoasthenoteratozoospermia. Collectively, our genetic analyses and experimental observations in humans and cynomolgus monkeys highlight the crucial role of TFDP3, an inhibitor of apoptosis, in normal spermatogenesis. These findings expand the spectrum of pathogenic variants for oligoasthenoteratozoospermia-associated male infertility and also reveal the special significance of primate-specific TFDP3 for the human male reproductive system, thus providing important guidance for genetic counseling and the clinical diagnosis of male infertility. - Source: PubMed
Publication date: 2026/01/27
Liu ChunyuTu ChaofengLi PengWu HuanWan FengLu YongTang ShuyanLi XinLi KuokuoWang JiaxiongGao YangGeng XinyanMeng LanlanZhou DapengZhou YilingZhou ZixueGuo HaibinCao YunxiaJin LiLi ZhengHe XiaojinTan Yue-QiuSun QiangZhang Feng - The increase in cancer incidence and mortality demonstrates the need for more effective anti-tumor therapies. Targeted therapies, such as cancer testicular antigens (CTAs), are promising as they are expressed in tumor cells but not in normal cells. TFDP3, a CTA expressed in cancers such as triple-negative breast cancer, prostate cancer, childhood T-cell lymphoblastic leukemia, and hepatocellular carcinoma, was chosen as a target for vaccine development. This study aimed to predict a multi-epitope vaccine based on TFDP3 using immunoinformatics tools to identify antigenic epitopes that interact with B lymphocytes, CD4+T lymphocytes, and CD8+T lymphocytes. Three epitopes from each lymphocyte type were selected, considering factors such as antigenicity, allergenicity, toxicity, IFN-γ induction, and population coverage. The vaccine also included adjuvants and ligands that ensure the stability and proper processing of the epitopes. The in-silico analysis revealed that the vaccine has favorable physicochemical properties, low homology with human proteins, and interactions with Toll-like receptors, ensuring stability. The population coverage world of the MHC class I and II epitopes were 93.55%. Additionally, the vaccine can be cloned and induce a robust immune response after three administrations. Despite the promising results, immunotherapy still faces challenges, such as tumor heterogeneity and immune evasion. In vitro and in vivo studies are necessary to assess the vaccine's efficacy and safety for future cancer treatments that express TFDP3. - Source: PubMed
Publication date: 2025/08/13
de Omena Neta Genilda Castroda Silva Junior Jose Wilson BatistaRocha Rodger Marcel Limada Silva Fernandes Duarte Ana KellyGomes Emisael Stenio BatistaZanchi Fernando Bertonde Sales Marques Carolinnede Carvalho Fraga Carlos Alberto - Transcription factor DP family member 3 (TFDP3) is a cancer-testis antigen, mainly expressed in normal testis and multiple cancers. gene (Gene ID: 51270) is located on the chromosome X and shares a high degree of sequence homology with TFDP1 and TFDP2, which can form heterodimers with E2F family members and enhance DNA-binding activity of E2Fs. In contrast to TFDP1 and TFDP2, TFDP3 downregulates E2F-mediated transcriptional activation. During DNA damage response in cancer cells, TFDP3 is induced and can inhibit E2F1-mediated apoptosis. Moreover, TFDP3 is involved in cell autophagy and epithelial-mesenchymal transition. Regarding cancer therapy opportunity, the transduction of dendritic cells with recombinant adenovirus-encoding TFDP3 can activate autologous cytotoxic T lymphocytes to target hepatoma cells. Here, we review the characterization of TFDP3, with an emphasis on the biological function and molecular mechanism. A better understanding of TFDP3 will provide new insights into the pathological mechanisms and therapeutic strategies for cancers. - Source: PubMed
Publication date: 2021/10/20
Huang JiahaoWang YiniLiu JinlongChu MingWang Yuedan - Epithelial cell transformation (EMT) plays an important role in the pathogenesis and metastasis of hepatocellular carcinoma (HCC). We aimed to establish a genetic risk model to evaluate HCC prognosis based on the expression levels of EMT-related genes. The data of HCC patients were collected from TCGA and ICGC databases. Gene expression differential analysis, univariate analysis, and lasso combined with stepwise Cox regression were used to construct the prognostic model. Kaplan-Meier curve, receiver operating characteristic (ROC) curve, calibration analysis, Harrell's concordance index (C-index), and decision curve analysis (DCA) were used to evaluate the predictive ability of the risk model or nomogram. GO and KEGG were used to analyze differently expressed EMT genes, or genes that directly or indirectly interact with the risk-associated genes. A 10-gene signature, including , , , , , , , , , and , was identified. Kaplan-Meier survival analysis showed a significant prognostic difference between high- and low-risk groups of patients. ROC curve analysis showed that the risk score model could effectively predict the 1-, 3-, and 5-year overall survival rates of patients with HCC. The nomogram showed a stronger predictive effect than clinical indicators. C-index, DCA, and calibration analysis demonstrated that the risk score and nomogram had high accuracy. The single sample gene set enrichment analysis results confirmed significant differences in the types of infiltrating immune cells between patients in the high- and low-risk groups. This study established a new prediction model of risk gene signature for predicting prognosis in patients with HCC, and provides a new molecular tool for the clinical evaluation of HCC prognosis. - Source: PubMed
Publication date: 2021/04/30
Wang XuequanXing ZimingXu HuihuiYang HaihuaXing Tongjing - Cancer-Testis antigens (CTA) are named after the tissues where they are mainly expressed: in germinal and in cancer cells, a process that mimics many gametogenesis features. Mapping accurately the CTA gene expression signature in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) is a prerequisite for downstream immune target-discovery projects. In this study, we take advantage of the use of azacitidine to treat high-risk MDS and CMML to draw the CTAs landscape, before and after treatment, using an targeted RNA sequencing (RNA-seq) design for this group of low transcript genes. In 19 patients, 196 CTAs were detected at baseline. Azacitidine did not change the number of CTAs expressed, but it significantly increased or decreased expression in nine and five CTAs, respectively. and , emerged as the main candidates for immunotherapeutic targeting, as they showed three main features: i) a significant derepression on day +28 of cycle one in those patients who achieved complete remission with hypomethylating treatment (FC = 6, = .008; FC = 2.1, = .008, respectively), ii) similar dynamics at the protein level to what was observed at the RNA layer, and iii) to elicit significant specific cytotoxic immune responses detected by TFDP3 and DDX53 HLA-A*0201 tetramers. Our study addresses the unmet landscape of CTAs expression in MDS and CMML and revealed a previously unrecognized and reactivation, detectable in plasma and able to elicit a specific immune response after one cycle of azacitidine. - Source: PubMed
Publication date: 2020/10/01
Hurtado López Ana MaríaChen-Liang Tzu HuaZurdo MaríaCarrillo-Tornel SalvadorPanadero JoaquínSalido Eduardo JoséBeltrán VictorMuiña BegoñaAmigo MariLuzNavarro-Villamor NoeliaCifuentes RosaCalabria InésAntón Ana IsabelTeruel RaúlMuro ManuelVicente VicenteJerez Andrés